Zhang Huza, Chambers William, Sciascia Savino, Cuadrado Maria J
a Louise Coote Lupus Unit , Guy's and St Thomas' NHS Foundation Trust , London , UK.
b Center of Research of Immunopathology and Rare Diseases- Coordinating Center of the Network for Rare Diseases of Piedmont and Aosta Valley, Department of Rare, Immunologic, Hematologic and Immunohematologic Diseases, and SCDU Nephrology and Dialysis , S. Giovanni Bosco Hospital and University of Turin , Turin , Italy.
Expert Rev Clin Pharmacol. 2016;9(5):681-94. doi: 10.1586/17512433.2016.1155446. Epub 2016 Mar 10.
Systemic lupus erythematous (SLE) is a chronic autoimmune disease characterised by multisystem involvement and a relapsing remitting course. SLE is a highly heterogeneous condition, with wide variations in both the presentation and severity of disease and the biological markers identified. The use of biologics in SLE has lagged behind that of other rheumatological conditions such as rheumatoid arthritis, in part due to the diverse clinical manifestations of SLE, making it difficult to design appropriate trials for novel treatments. As such, broad immunosuppressive treatment regimens are still widely used in SLE. Nevertheless, in recent years, elucidation of some aspects of SLE pathogenesis have allowed the development of therapies targeted at molecular mediators of SLE. This review provides an update of biological available therapies and those currently under development.
系统性红斑狼疮（SLE）是一种慢性自身免疫性疾病，其特征为多系统受累且病情呈复发缓解过程。SLE是一种高度异质性疾病，疾病的表现、严重程度以及所识别的生物标志物均存在广泛差异。与类风湿关节炎等其他风湿性疾病相比，生物制剂在SLE中的应用较为滞后，部分原因是SLE临床表现多样，难以设计出针对新型治疗方法的合适试验。因此，广泛的免疫抑制治疗方案仍在SLE中广泛使用。然而，近年来，对SLE发病机制某些方面的阐明使得针对SLE分子介质的治疗方法得以发展。本综述提供了生物可用疗法以及目前正在研发的疗法的最新情况。
